MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US SAN DIEGO, February 12, 2026--(BUSINESS ...
MedImpact’s attempt to recoup approximately $200 million following its purchase of Rite Aid Corp’s (OTC:RADCQ) pharmacy benefits unit has failed. U.S. Bankruptcy Judge Michael Kaplan ruled that ...
SAN DIEGO, April 28, 2026--(BUSINESS WIRE)--MedImpact, the nation’s largest independent pharmacy benefit and health solutions company, today announced the expansion of its MedEmpower Fuel™ platform ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Precision medicine’s promise is to determine for each individual ...
Rite Aid said U.S. Bankruptcy Court has approved the sale of its Elixir pharmacy benefit management (PBM) company to MedImpact for $575 million. Rite Aid is selling its Elixir pharmacy benefit ...
SAN DIEGO--(BUSINESS WIRE)--MedImpact, the nation’s largest privately held pharmacy benefit manager (PBM), was awarded PBMI’s Excellence Award in the Cost Containment category for its submission on ...
SAN DIEGO--(BUSINESS WIRE)--MedImpact Healthcare Systems, Inc., the nation’s largest privately held provider of pharmacy benefit management (PBM) services, today announced it will acquire Apex ...
MedImpact Healthcare Systems, an independent provider of health solutions, technology and pharmacy benefit services, is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz, for new ...
SAN DIEGO, Calif. -- MedImpact Healthcare Systems Inc. has won a 39-month contract to provide pharmacy benefit management services to the University of Michigan's Prescription Drug Plan. The ...
MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...
MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (Adalumymab-ryvk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results